SC
RAPT

Samlyn Capital’s RAPT Therapeutics RAPT Stock Holding History

Samlyn Capital’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-88,941
Closed -$17.7M – 113
2023
Q4 		$17.7M Buy
+88,941
New +$11M 0.35% 65
2023
Q2 		– Sell
-23,283
Closed -$3.42M – 107
2023
Q1 		$3.42M Buy
+23,283
New +$4.71M 0.06% 86

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Samlyn Capital's RAPT Position: Q1 2024 in Review

Samlyn Capital sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 88,941 shares — an estimated $17.7M sold.

Samlyn Capital first reported a position in RAPT in Q1 2023 and held it in 2 quarters. The position peaked at $17.7M in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • Samlyn Capital reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Samlyn Capital sold 88,941 RAPT Therapeutics shares in Q1 2024, an estimated $17.7M.
  • Samlyn Capital first reported a position in RAPT Therapeutics in Q1 2023 and held it in 2 quarters.
  • Samlyn Capital's RAPT Therapeutics position peaked at $17.7M in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Samlyn Capital's 13F filing for Q1 2024, filed 15 May 2024.